查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933317

全球重組疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量、未來預測（2026-2034）

Recombinant Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

重組疫苗市場成長因素

由於傳染病日益流行、對安全有效疫苗的需求不斷成長以及主要製藥公司的策略投資，全球重組疫苗市場預計將穩步成長。該市場在2025年的價值為415.9億美元，預計2026年達到448.6億美元，到2034年成長至1090.6億美元，預測期內年複合成長率為10.62%。

重組疫苗利用基因工程技術標靶特定基因或蛋白質，誘發有針對性的免疫反應。與傳統疫苗相比，它們具有高特異性、可擴展性和安全性等優勢。例如，2023年5月，GSK的重組疫苗Aleksvy獲得美國FDA批准，用於預防60歲及以上成年人由呼吸道合胞病毒（RSV）引起的下呼吸道疾病。

市場由Bavarian Nordic、GSK plc、Pfizer Inc.、Merck & Co., Inc.等大型公司主導，它們強大的產品組合和全球分銷網路鞏固了其領先地位。

市場動態

市場驅動因素

關鍵成長因素之一是研發投入的增加。重組疫苗無需使用完整的病原體即可開發，降低感染風險和不良反應。各公司正大力投資研發此類疫苗，以滿足不斷成長的需求。例如，2024年9月，美國國際發展金融公司（DFC）向Panacea Biotech公司提供了一筆高達2000萬美元的貸款，用於資助其基於IPV的重組脊髓灰質炎疫苗EasySix的研發。

市場限制因子

疫苗研發的高昂成本和臨床試驗失敗的風險限制市場成長。疫苗生產需要複雜的細胞培養系統、純化過程和昂貴的生物反應器，增加了資本支出。例如，2023年8月，GSK plc投資2.706億美元，用於擴大其在比利時的重組疫苗產能。同樣，2025年8月，美國衛生與公共服務部（HHS）終止了生物醫學高級研究與發展局（BARDA）的mRNA疫苗研發活動，理由是該疫苗對某些傳染病的保護作用不足。

市場機會

治療性疫苗的研發為市場擴張提供了巨大的機會。針對癌症和病毒感染的重組疫苗具有標靶治療優勢。2025年3月，ImmunityBio與Urology Partners合作，擴大膀胱癌患者使用重組卡介苗（rBCG）免疫療法的途徑。同樣，2024年6月，Moderna和Merck & Co., Inc.公佈了針對黑色素瘤患者的個人化重組mRNA癌症疫苗II期臨床試驗的積極資料。

市場挑戰

冷鏈物流和供應方面的挑戰仍然是重大障礙。重組疫苗對溫度敏感，需要嚴格冷藏才能維持效力。中低收入國家往往面臨基礎建設的挑戰，限制了疫苗的供應。例如，2021年9月，世界衛生組織向45個國家提供了350台超低溫冰箱，以應對這些限制。

市場趨勢

一個值得關注的趨勢是聯合疫苗的研發，這種疫苗只需一劑即可預防多種疾病。這提高了接種依從性，並減少了儲存方面的挑戰。2024年12月，Sanofi公司針對50歲及以上成年人研發的流感和新冠肺炎聯合疫苗獲得了快速通道資格認定。

市場區隔分析

依類型劃分：

  • 由於次單位疫苗具有高穩定性、安全性和靶向免疫反應等優點，預計到2026年，亞單位疫苗將佔據市場主導地位，市場佔有率高達77.11%。例如，印度在其 "新冠安全使命" （Mission COVID Suraksha）計劃下研發了蛋白質亞單位新冠疫苗 "ORBEVAX™" 。
  • 載體疫苗也越來越受歡迎，但其市場佔有率仍然相對較小。

依疾病分類：

  • 受疾病盛行率上升和產能擴張的推動，HPV疫苗將在2026年佔據市場主導地位，市場佔有率達38.29%。Merck & Co., Inc.於2022年4月擴建了位於維吉尼亞州埃爾克頓的工廠，以供應HPV疫苗。
  • 預計B肝疫苗在預測期內將以15.1%的年複合成長率成長。

依給藥途徑分類：

  • 由於注射疫苗具有高生物利用度和標靶作用，到2026年，注射疫苗將佔據主導地位，市場佔有率達78.38%。例如，Valneva公司於2023年11月獲得了FDA批准的首個注射型屈公病疫苗Ixchiq。
  • 預計口服疫苗將顯著成長。

依通路劃分：

  • 2024年，政府供應商佔據主導地位，他們積極推廣常規免疫接種計劃，尤其是在中低收入地區。
  • 2026年，醫院和零售藥局的市場佔有率達到60.89%。策略夥伴關係進一步鞏固了這個通路，例如Merck與全球疫苗免疫聯盟（Gavi）和聯合國兒童基金會（UNICEF）合作，計劃到2025年供應1.15億劑HPV疫苗。

區域展望

  • 北美成為最大的市場，2025年市場規模達到177.5億美元，預計到2026年將成長至192.2億美元，這主要得益於其先進的醫療保健基礎設施和較高的疫苗接種率。
  • 2025年，歐洲市場規模達到81.1億美元，實現強勁成長（年複合成長率8.68%）。英國和德國市場預計到2026年將分別達到17.3億美元和21.1億美元。
  • 到2025年，亞太地區市場規模達到97.4億美元；到2026年，日本、中國和印度市場規模分別達到16.1億美元、25.3億美元和22.3億美元。
  • 到2025年，拉丁美洲市場規模達到20.9億美元；中東和非洲（GCC）地區市場規模達到1.8億美元，這兩個地區都溫和成長。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 各國及地區主要疾病概覽（2025年）
  • 各國及地區監理狀況（2025年）
  • 主要公司研發管線分析
  • 疫苗市場技術進步
  • 主要公司新產品發布
  • 關鍵產業趨勢：併購、業務合作等等。

第5章 全球重組疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型劃分
    • 次單位疫苗
    • 載體疫苗
  • 市場分析、洞察與預測：依疾病劃分
    • 人類乳突病毒（HPV）
    • 帶狀皰疹
    • B型肝炎
    • 其他
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 注射
  • 市場分析、洞察與預測：依通路劃分
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美重組疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲重組疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 其他歐洲國家

第8章 亞太地區重組疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章 拉丁美洲重組疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區美國

第10章 中東與非洲重組疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • GCC國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
  • Bavarian Nordic
  • GSK plc
  • Pfizer Inc.
  • Merck &Co., Inc.
  • CSL
  • Mitsubishi Chemical Group Corporation
  • AstraZeneca
  • Sanofi
  • EMERGENT
  • BIKEN.
Product Code: FBI101935

Growth Factors of recombinant vaccines Market

The global recombinant vaccines market is poised for robust growth owing to increasing prevalence of infectious diseases, rising demand for safe and effective vaccines, and strategic investments by leading pharmaceutical companies. The market was valued at USD 41.59 billion in 2025, expected to reach USD 44.86 billion in 2026, and projected to grow to USD 109.06 billion by 2034, reflecting a CAGR of 10.62% during the forecast period.

Recombinant vaccines are genetically engineered vaccines that target specific genes or proteins to elicit a focused immune response. These vaccines offer high specificity, scalability, and safety advantages compared to traditional vaccines. For example, in May 2023, GSK received U.S. FDA approval for Arexvy, a recombinant vaccine for preventing lower respiratory tract disease caused by RSV in adults aged 60 years and older.

The market is dominated by key players such as Bavarian Nordic, GSK plc, Pfizer Inc., and Merck & Co., Inc., whose strong product portfolios and global distribution networks contribute to their leading positions.

Market Dynamics

Market Drivers

One of the major growth drivers is the rising investment in research and development. Recombinant vaccines can be developed without using the entire pathogen, reducing the risk of infection and adverse events. Companies are heavily investing in developing these vaccines to meet growing demand. For instance, in September 2024, the U.S. International Development Finance Corporation (DFC) provided a loan of up to USD 20 million to Panacea Biotec Limited for developing an IPV-based recombinant polio vaccine, EasySix.

Market Restraints

The high cost of vaccine development and risk of clinical trial failures restrict market growth. Production involves advanced cell culture systems, purification processes, and expensive bioreactors, increasing capital expenditure. For example, in August 2023, GSK plc invested USD 270.6 million to expand recombinant vaccine capacity in Belgium. Similarly, in August 2025, the U.S. HHS terminated mRNA vaccine development activities under BARDA due to ineffective protection against certain infections.

Market Opportunities

The development of therapeutic vaccines offers significant opportunities for market expansion. Recombinant vaccines for cancer or viral infections provide targeted therapeutic benefits. In March 2025, ImmunityBio, Inc. partnered with U.S. Urology Partners to expand access for recombinant BCG (rBCG) immunotherapy for bladder cancer. Likewise, in June 2024, Moderna and Merck reported positive Phase 2 data for a personalized recombinant mRNA cancer vaccine in melanoma patients.

Market Challenges

Cold chain logistics and supply challenges remain critical barriers. Recombinant vaccines are temperature-sensitive, requiring strict cold storage to maintain efficacy. Low- and middle-income countries often face infrastructure challenges, restricting vaccine accessibility. For example, in September 2021, the WHO delivered 350 ultra-cold chain freezers to over 45 countries to address these limitations.

Market Trends

A prominent trend is the development of combination vaccines that provide protection against multiple diseases in a single shot, improving compliance and reducing storage challenges. In December 2024, Sanofi received Fast Track designation for combination vaccines targeting influenza and COVID-19 in adults above 50 years.

Segmentation Analysis

By Type:

  • Subunit vaccines dominated in 2026 with 77.11% share, driven by high stability, safety, and targeted immune response. For example, India developed ORBEVAXTM, a protein subunit COVID-19 vaccine, under the Mission COVID Suraksha initiative.
  • Vector-based vaccines are also gaining traction but represent a smaller share.

By Disease Indication:

  • HPV vaccines led in 2026 with 38.29% share, supported by rising disease prevalence and expanded production capacities. Merck & Co., Inc. expanded its Elkton, Virginia facility in April 2022 for HPV vaccine supply.
  • Hepatitis B vaccines are projected to grow at a 15.1% CAGR during the forecast period.

By Route of Administration:

  • Parenteral vaccines dominated in 2026 with 78.38% share, due to greater bioavailability and site-specific action. For instance, Valneva SE received FDA approval in November 2023 for Ixchiq, the first parenteral chikungunya vaccine.
  • Oral vaccines are expected to grow at a significant rate.

By Distribution Channel:

  • Government suppliers dominated in 2024, facilitating routine vaccination programs, especially in low- and middle-income regions.
  • Hospitals and retail pharmacies held 60.89% share in 2026. Strategic collaborations, such as Merck's partnership with Gavi and UNICEF to supply 115 million HPV vaccine doses by 2025, further strengthened this channel.

Regional Outlook

  • North America dominated with USD 17.75 billion in 2025, growing to USD 19.22 billion in 2026, driven by advanced healthcare infrastructure and high vaccine adoption.
  • Europe was valued at USD 8.11 billion in 2025, with projected strong growth (8.68% CAGR). The UK and Germany markets are expected to reach USD 1.73 billion and USD 2.11 billion by 2026, respectively.
  • Asia Pacific reached USD 9.74 billion in 2025, with Japan, China, and India markets projected at USD 1.61 billion, 2.53 billion, and 2.23 billion by 2026, respectively.
  • Latin America recorded USD 2.09 billion in 2025, while Middle East & Africa (GCC) stood at USD 0.18 billion in 2025, with moderate growth expected.

Competitive Landscape

The market is semi-consolidated, dominated by Bavarian Nordic, GSK plc, Pfizer Inc., and Merck & Co., Inc.. Other players include Mitsubishi Chemical, AstraZeneca, Sanofi, EMERGENT, and BIKEN, focusing on product innovation, strategic partnerships, and geographic expansion.

Key Developments:

  • July 2025: GSK approved prefilled syringe of Shingrix (zoster vaccine).
  • April 2025: GC Biopharma approved for anthrax vaccine BARYTHRAX in South Korea.
  • March 2024: IIT Guwahati launched recombinant vaccine for Swine Fever Virus.
  • May 2023: Pfizer received FDA approval for ABRYSVO (RSV vaccine).

Conclusion

The global recombinant vaccines market is projected to grow from USD 41.59 billion in 2025 to USD 109.06 billion by 2034, at a CAGR of 10.62%. Growth is driven by rising infectious disease prevalence, investments in R&D, development of subunit and combination vaccines, and expansion of therapeutic applications. Despite challenges such as high manufacturing costs and cold chain logistics, opportunities in HPV, hepatitis B, and therapeutic cancer vaccines, along with strategic collaborations, will continue to propel market expansion globally.

Segmentation By Type

  • Subunit Vaccines
  • Vector-Based Vaccines

By Disease Indication

  • HPV
  • Herpes Zoster
  • Hepatitis B
  • Others

By Route of Administration

  • Parenteral
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Key Diseases, By Key Countries/ Region, 2025
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2025
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Technological Advancements in the Vaccines Market
  • 4.5. New Product Launches, By Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Subunit Vaccines
    • 5.1.2. Vector-Based Vaccines
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Human Papillomavirus (HPV)
    • 5.2.2. Herpes Zoster
    • 5.2.3. Hepatitis B
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Subunit Vaccines
    • 6.1.2. Vector-Based Vaccines
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Human Papillomavirus (HPV)
    • 6.2.2. Herpes Zoster
    • 6.2.3. Hepatitis B
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Subunit Vaccines
    • 7.1.2. Vector-Based Vaccines
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Human Papillomavirus (HPV)
    • 7.2.2. Herpes Zoster
    • 7.2.3. Hepatitis B
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Subunit Vaccines
    • 8.1.2. Vector-Based Vaccines
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Human Papillomavirus (HPV)
    • 8.2.2. Herpes Zoster
    • 8.2.3. Hepatitis B
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Subunit Vaccines
    • 9.1.2. Vector-Based Vaccines
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Human Papillomavirus (HPV)
    • 9.2.2. Herpes Zoster
    • 9.2.3. Hepatitis B
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Subunit Vaccines
    • 10.1.2. Vector-Based Vaccines
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Human Papillomavirus (HPV)
    • 10.2.2. Herpes Zoster
    • 10.2.3. Hepatitis B
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. Bavarian Nordic
    • 11.2.2. GSK plc
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Merck & Co., Inc.
    • 11.2.5. CSL
    • 11.2.6. Mitsubishi Chemical Group Corporation
    • 11.2.7. AstraZeneca
    • 11.2.8. Sanofi
    • 11.2.9. EMERGENT
    • 11.2.10. BIKEN.

List of Tables

  • Table 1: Global Recombinant Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Recombinant Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 3: Global Recombinant Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Recombinant Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Recombinant Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 7: North America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 8: North America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Recombinant Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Recombinant Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 12: Europe Recombinant Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 13: Europe Recombinant Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Recombinant Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Recombinant Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Recombinant Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 17: Asia Pacific Recombinant Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 18: Asia Pacific Recombinant Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Recombinant Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Recombinant Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Latin America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 23: Latin America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Recombinant Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Recombinant Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 27: Middle East & Africa Recombinant Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 28: Middle East & Africa Recombinant Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Recombinant Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Recombinant Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Recombinant Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Recombinant Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Recombinant Vaccines Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 4: Global Recombinant Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Recombinant Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Recombinant Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Recombinant Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 8: North America Recombinant Vaccines Market Value Share (%), by Type, 2025
  • Figure 9: North America Recombinant Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 10: North America Recombinant Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 11: North America Recombinant Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Recombinant Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Recombinant Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Recombinant Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Recombinant Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Recombinant Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Recombinant Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 18: Europe Recombinant Vaccines Market Value Share (%), by Type, 2025
  • Figure 19: Europe Recombinant Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 20: Europe Recombinant Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 21: Europe Recombinant Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Recombinant Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Recombinant Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Recombinant Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Recombinant Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Recombinant Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Recombinant Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 28: Asia Pacific Recombinant Vaccines Market Value Share (%), by Type, 2025
  • Figure 29: Asia Pacific Recombinant Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 30: Asia Pacific Recombinant Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 31: Asia Pacific Recombinant Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Recombinant Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Recombinant Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Recombinant Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Recombinant Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Recombinant Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Recombinant Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 38: Latin America Recombinant Vaccines Market Value Share (%), by Type, 2025
  • Figure 39: Latin America Recombinant Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 40: Latin America Recombinant Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 41: Latin America Recombinant Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Recombinant Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Recombinant Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Recombinant Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Recombinant Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Recombinant Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Recombinant Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 48: Middle East & Africa Recombinant Vaccines Market Value Share (%), by Type, 2025
  • Figure 49: Middle East & Africa Recombinant Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 50: Middle East & Africa Recombinant Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 51: Middle East & Africa Recombinant Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Recombinant Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Recombinant Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Recombinant Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Recombinant Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Recombinant Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Recombinant Vaccines Market Share (%), By Company, 2025